MCM
PCVX icon

Manchester Capital Management’s Vaxcyte PCVX Stock Holding History

Manchester Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,500
Closed -$76.5K – 1062
2023
Q3 		$76.5K Hold
1,500
– – 0.01% 376
2023
Q2 		$74.9K Hold
1,500
– – 0.01% 378
2023
Q1 		$56.2K Hold
1,500
– – 0.01% 415
2022
Q4 		$71.9K Hold
1,500
– – 0.01% 346
2022
Q3 		$36K Hold
1,500
– – 0.01% 378
2022
Q2 		$33K Hold
1,500
– – 0.01% 385
2022
Q1 		$36K Hold
1,500
– – 0.01% 417
2021
Q4 		$36K Hold
1,500
– – ﹤0.01% 421
2021
Q3 		$38K Buy
+1,500
New +$36.4K 0.01% 448

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Manchester Capital Management's PCVX Position: Q4 2023 in Review

Manchester Capital Management sold out of Vaxcyte (PCVX) in Q4 2023, closing a stake of 1,500 shares — an estimated $76.5K sold.

Manchester Capital Management first reported a position in PCVX in Q3 2021 and held it in 9 quarters. The position peaked at $76.5K in Q3 2023. 223 funds tracked by Wall St. Rank hold PCVX as of Q4 2023.

  • Manchester Capital Management reported no remaining Vaxcyte position as of Q4 2023 after selling out during the quarter.
  • Manchester Capital Management sold 1,500 Vaxcyte shares in Q4 2023, an estimated $76.5K.
  • Manchester Capital Management first reported a position in Vaxcyte in Q3 2021 and held it in 9 quarters.
  • Manchester Capital Management's Vaxcyte position peaked at $76.5K in Q3 2023.
  • 223 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2023.

Based on Manchester Capital Management's 13F filing for Q4 2023, filed 8 Feb 2024.